Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
Hidden Barriers Could Contribute to Rising Colorectal Cancer Deaths in Adults Under 50
As the nation observes Women's Health Month (beginning on Mother's Day) and Clinical Trials Awareness Month, the leading nonprofit Colorectal Cancer Alliance (Alliance) is calling on patients, caregivers, and healthcare providers to confront the urgent and underrecognized public health challenges that may be contributing to the rising death rates.
In Memoriam: Asal Sayas
Asal Sayas, a force for good in public policy and a champion for patients, who worked for both a president and a senator, died Tuesday, April 21, after a defiant six-year path with young-onset colorectal cancer. She was 42 years old.
LEAD FROM BEHIND Honored with Prestigious Webby Award
The Colorectal Cancer Alliance LEAD FROM BEHIND initiative featuring Katie Couric is a winner in the 30th Annual Webby Awards.